Henceforth, this study aimed to describe the long-term burden of cardiovascular mortality and hospitalizations in patients with PCa receiving ADT. Long-term cardiovascular burden in prostate cancer patients receiving androgen deprivation therapy In this study, we quantified the long-term burden of cardiovascular mortality and hospitalizations in a representative, prospective, population-based cohort of Hong Kong patients with PCa receiving ADT. Keywords: androgen deprivation therapy; cardio-oncology; epidemiology; prostate cancer EN androgen deprivation therapy cardio-oncology epidemiology prostate cancer 1 5 5 03/15/23 20230401 NES 230401 Androgen deprivation therapy (ADT), which pharmacologically or surgically suppresses androgen activity, is a key treatment for prostate cancer (PCa).[1] However, it is associated with increased cardiovascular risks, including elevated risks of cardiovascular mortality, myocardial infarction and stroke.[[2]] Nonetheless, prior studies have focussed on the first occurrence of adverse cardiovascular events,[[2], [4]] and the burden of cardiovascular hospitalizations in patients with PCa receiving ADT has remained unexplored. [Extracted from the article]